Barclays analyst Eliana Merle raised the firm’s price target on PTC Therapeutics (PTCT) to $120 from $119 and keeps an Overweight rating on the shares post the Q4 report. The firm sees potential upside to the company’s 2026 revenue outlook.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $82 from $78 at RBC Capital
- PTC Therapeutics price target lowered to $93 from $97 at BofA
- Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics
- PTC Therapeutics price target lowered to $86 from $93 at Wells Fargo
- PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating